Vivos Therapeutics Inc
VVOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.64M
Close$
Share Statistics
| Market cap | $2.64 Million |
|---|---|
| Enterprise Value | $12.38 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.06 |
| Beta | 6.08 |
| Outstanding Shares | 14,634,115 |
Return
| Return on Equity | 2201.14% |
|---|---|
| Return on Assets | -100.02% |
| Return on Invested Capital | -317.97% |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | -0.2 |
| Price to Sales | 0.45 |
| Price to Book Ratio | -0.45 |
| Enterprise Value to Revenue | 0.63 |
| Enterprise Value to EBIT | -0.55 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.96 |
| Debt to Equity | -10.41 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$4.35 M
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$5.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.62%▲ 10.62% |
|---|---|
| Total Invested | $2.15M▲ 60.71% |
| Investors Holding | 23▲ 5.00% |
ESG Score
No data
About Vivos Therapeutics Inc
115 employeesVivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that...